Urgo Medical

The Clinical Trial EXPLORER is the First Study to Demonstrate the Efficacy of a Dressing (Urgostart®) in Diabetic Foot Ulcer Healing - Seite 2

The results: 

• A significantly higher healing rate compared to a well-managed standard treatment, representing +60% more patients healed.

• A significantly shorter healing time (reduced by 60 days) compared with the average healing time in the control group of 180 days.

• When the UrgoStart treatment is initiated early, it significantly increases the chances of the patient being healed compared to a well-managed standard treatment.

"Each day that a patient with diabetes has a foot ulcer, there is the risk of infection and amputation. The Explorer study showed that UrgoStart healed more neuro-ischaemic foot ulcers than standard treatment and on average 60 days more quickly.  This reduces the risk of infection and saves money," enthuses Dr. Michael Edmonds, Professor of Diabetic Foot Medicine at King's College Hospital (London).

"The Lancet Diabetes & Endocrinology is one of the most respected international scientific journals. Publication of the EXPLORER study in such a prestigious journal underlines the quality of the study and the significance of its results", specifies Gavin Ashton, Urgo UK Managing Director. "More than a dressing, it is a genuine treatment that has a full role to play in the protocol for chronic foot ulcers in diabetic patients."

Find out more about Urgo Medical: 

Please visit http://www.urgo.co.uk

UrgoStart®: Indications: the treatment of chronic wounds (leg ulcers, pressure ulcers, diabetic foot wounds and acute wounds that have become chronic). Please read the leaflet carefully.

Class IIb medical device (GMed)

Manufacturer: Laboratoires URGO.

*TLC matrix impregnated with NOSF (Nano OligoSaccharide Factor) = KSOS (potassium sucrose octasulfate) 

References:

1. Edmonds M, Lázaro JL, Piaggesi A, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. The Lancet Diabetes & Endocrinology. 20 December 2017. Online. (20^th March 2018 in print)
2. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376: 2367-75
3. International Diabetes Federation. IDF Diabetes Atlas 7th edition; 2015.http://www.diabetesatlas.org (accessed 9 June, 2016).
4. Whiting, D. R., Guariguata, L., Weil, C., and Shaw, J. 2011. "IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030." Diabetes Res. Clin. Pract. 94 (3): 311-21.
5. National Diabetes Foot Care Audit Report 2014-2016 - NHS Digital, https://digital.nhs.uk/catalogue/PUB23525 (accessed 19 February 2018)
6. Walsh JW, Hoffstad OJ, Sullivan MO, Margolis DJ. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med 2016; 33: 1493-8.

 

Press contact:
Urgo Medical UK
Gavin Ashton
[phone]
[e-mail]